| Ticker Symbol: | BNVI |
|---|---|
| Exchange: | NASD |
| Contact Info: | 5858 Horton Street Emeryville CA 94608 510-601-2000 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | BIONOVO INC is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women\'s health and cancer, which are markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology ofmenopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California |
| Shares Outstanding: | 76,340 (000) | Market Value: | 86,290 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 8.16% | Number of Inst.Shareholders: | 26.30% |
| Last Quarter Sales: | 0.00 ($Mil.) | Last Quarter Net Income: | -4.21 ($Mil.) |
| Last Quarter EPS: | -0.06 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.21 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +46.20 | 65.06 | |
| GILEAD SCIENCES | +45.50 | 56.26 | |
| GENENTECH INC | +47.20 | 98.23 | |
| BIOGEN IDEC INC | -1.20 | 54.65 | |
| CELGENE CP | +36.60 | 75.86 |
